Particle Immunofiltration Assay ("Pifa") was Q’s largest revenue line in fiscal 2018, bringing in $1.42M of $1.67M (85%).
| Legal Entity | FY 2017 | FY 2018 |
|---|---|---|
| Particle Immunofiltration Assay ("Pifa") | $2.23M | $1.42M |
| Other | $556.95K | $50.52K |
| Microparticle Catalyzed Biosensor ("Mpc") | $381.23K | $123.94K |
| Rapid Enzymatic Assay ("Rea") | $133.85K | $68.75K |
| Total | $3.30M | $1.67M |
Q brought in $1.67M from its four revenue lines in fiscal 2018, the year ended December 31, 2018. That was down 49.6% from $3.30M in fiscal 2017. Particle Immunofiltration Assay ("Pifa") was the largest at $1.42M (85.4%), ahead of Microparticle Catalyzed Biosensor ("Mpc") at $123.94K (7.4%) and Rapid Enzymatic Assay ("Rea") at $68.75K (4.1%). The remaining revenue line, Other, brought in $50.52K.
Compared with fiscal 2017, every revenue line above 2% of revenue shrank. Particle Immunofiltration Assay ("Pifa") held up best, down 36.3% to $1.42M, and Other fell the most, down 90.9% to $50.52K.
United States was Q’s largest region in fiscal 2018, bringing in $1.58M of $1.67M (95%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|
| United States | $1.58M | $2.33M | $2.68M | $1.58M |
| People's Republic Of China | $37.51K | $503.00K | $502.13K | — |
| Rest Of World | $498.45K | $127.19K | $173.03K | $88.81K |
| Total | $2.12M | $2.96M | $3.35M | $1.67M |
Q brought in $1.67M from its two regions in fiscal 2018, the year ended December 31, 2018. Q regrouped these regions after fiscal 2017, so the total does not compare directly with that year's $3.35M. United States was the largest at $1.58M (94.7%), ahead of Rest Of World at $88.81K (5.3%).
Compared with fiscal 2017, United States fell 41.2% to $1.58M and Rest Of World fell 48.7% to $88.81K.
Q stopped reporting People's Republic Of China as a separate region after fiscal 2017, when it brought in $502.13K.
Q (QCLS) reports its revenue by legal entity and by geography. In fiscal 2018, Particle Immunofiltration Assay ("Pifa") was its largest revenue line, bringing in $1.42M (85.4% of the total), followed by Microparticle Catalyzed Biosensor ("Mpc") at $123.94K (7.4%).
Particle Immunofiltration Assay ("Pifa") was Q's largest revenue line in fiscal 2018, bringing in $1.42M, or 85.4% of the $1.67M total across its four revenue lines.
United States was Q's largest region in fiscal 2018, bringing in $1.58M, or 94.7% of the $1.67M total across its two regions.
Every figure comes from Q's annual financial filings, as reported. Each line keeps the name Q gives it, and years follow its fiscal calendar.
Q's revenue by legal entity goes back to fiscal 2017, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.